XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended 35 Months Ended 45 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Jun. 30, 2023
Dec. 31, 2022
Mar. 31, 2022
Sep. 30, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Feb. 28, 2009
Feb. 28, 2009
Mar. 21, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Total revenue             $ 147,752,000 $ 140,734,000 $ 235,309,000      
Unbilled contract asset       $ 17,488,000     26,481,000 17,488,000        
Deferred Revenue       12,739,000     12,740,000 12,739,000        
Drug Product Revenue, Net [Member]                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Total revenue             18,753,000 $ 11,086,000 $ 962,000      
Japan [Member]                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Transaction price, variable consideration from estimated future co-development billing             0          
Japan [Member] | Drug Product Revenue, Net [Member]                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Total revenue     $ 14,400,000 $ 8,400,000 $ 9,800,000              
Europe [Member]                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Transaction price, variable consideration from estimated future co-development billing             $ 0          
Astellas Agreement [Member] | Japan [Member]                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Upfront, non-contingent and time-based payments received                     $ 40,100,000  
Potential milestone payments   $ 132,500,000                    
Commercial sales milestone   15,000,000.0                    
Additional consideration based on net sales description             the low 20% range of the list price          
Aggregate considerations received excluding drug product revenue             $ 105,100,000          
Changes in revenue from changes to estimated variable consideration             $ 0          
Astellas Agreement [Member] | Japan [Member] | Clinical and Development Milestone [Member]                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Potential milestone payments   22,500,000                    
Astellas Agreement [Member] | Japan [Member] | Regulatory Milestone [Member]                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Potential milestone payments   $ 95,000,000.0                    
Astellas Agreement [Member] | Europe [Member]                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Upfront, non-contingent and time-based payments received                   $ 320,000,000.0    
Potential milestone payments           $ 120,000,000.0            
Additional consideration based on net sales description             low 20% range          
Transaction price and allocated to performance obligations           $ 120,000,000.0           $ 25,000,000
Aggregate considerations received excluding drug product revenue             $ 685,000,000          
Development and regulatory approval milestones $ 425,000,000.0                      
Percentage of joint development costs committed to fund 50.00%                      
Changes in revenue from changes to estimated variable consideration             $ 0          
Astellas Agreement [Member] | Europe [Member] | Clinical and Development Milestone [Member]                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Potential milestone payments $ 90,000,000.0                      
Astellas Agreement [Member] | Europe [Member] | Regulatory Milestone [Member]                        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                        
Potential milestone payments $ 335,000,000.0